Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

被引：449

作者：

Crews, K. R. ^{[1
]}

Gaedigk, A. ^{[2
,3
]}

Dunnenberger, H. M. ^{[1
]}

Leeder, J. S. ^{[2
,3
]}

Klein, T. E. ^{[4
]}

Caudle, K. E. ^{[1
]}

Haidar, C. E. ^{[1
]}

Shen, D. D. ^{[5
,6
]}

Callaghan, J. T. ^{[7
,8
]}

Sadhasivam, S. ^{[9
,10
]}

Prows, C. A. ^{[11
,12
]}

Kharasch, E. D. ^{[13
]}

Skaar, T. C. ^{[7
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Therapeut Innovat, Kansas City, MO USA

[3] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[4] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[5] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA

[6] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA

[7] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

[8] RLR VA Med Ctr, Dept Vet Affairs, Indianapolis, IN USA

[9] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA

[10] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA

[11] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA

[12] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Cincinnati, OH 45229 USA

[13] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 04期

基金：

美国医疗保健研究与质量局;

关键词：

CYP2D6 ACTIVITY SCORE; BREAST-FED NEONATE; ULTRARAPID-METABOLISM; MORPHINE FORMATION; CANCER-PATIENTS; OXYCODONE; TRAMADOL; PHARMACOKINETICS; PHENOTYPE; PHARMACODYNAMICS;

D O I：

10.1038/clpt.2013.254

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

引用

页码：376 / 382

页数：7

共 50 条

[21] Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy
Rae, J. M.
Sikora, M. J.
Henry, N. L.
Li, L.
Kim, S.
Oesterreich, S.
Skaar, T.
Nguyen, A. T.
Desta, Z.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S21 - S21
[22] Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update
Martin, M. A.
Hoffman, J. M.
Freimuth, R. R.
Klein, T. E.
Dong, B. J.
Pirmohamed, M.
Hicks, J. K.
Wilkinson, M. R.
Haas, D. W.
Kroetz, D. L.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) : 499 - 500
[23] Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol
Duricova, J.
Perinova, I
Jurckova, N.
Jeziskova, I
Kacirova, I
Grundmann, M.
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2013, 114 (04): : 206 - 212
[24] Cytochrome P450 (CYP) 2D6 influences codeine metabolism in sickle cell disease (SCD).
Shord, S. S.
Molokie, R. E.
Cavallari, L. H.
Gao, W.
Jeong, H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S51 - S51
[25] A DISCORDANCE BETWEEN P450 2D6 GENOTYPE AND PHENOTYPE
Duricova, J.
Perinova, I
Kacirova, I
Grundmann, M.
Jeziskova, I
Jurckova, N.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 75 - 75
[26] The endocannabinoid anandamide is a substrate of cytochrome P450 2D6
Snider, Natasha Tasheva
Sridar, Chitra
Hollenberg, Paul
FASEB JOURNAL, 2008, 22
[27] Oxidation of methoxytyramines by recombinant cytochrome P450 2D6
Hanna, IH
Nishimura, Y
Miller, GP
Rizzo, CJ
Guengerich, FP
FASEB JOURNAL, 2000, 14 (08): : A1335 - A1335
[28] Hot flushes, tamoxifen and cytochrome P450 2D6
Boutet, G.
ONCOLOGIE, 2012, 14 (6-7) : 357 - 364
[29] Cytochrome P450 2D6 genetic polymorphisms of ugandans
Miura, I.
Saito, K.
Obua, C.
Abbo, C.
Kaneko, S.
Tateishi, T.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 103 - 103
[30] The role of cytochrome P450 2D6 in the metabolism of moclobemide
Hartter, S
Dingemanse, J
Baier, D
Ziegler, G
Hiemke, C
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1996, 6 (03) : 225 - 230

← 1 2 3 4 5 →